The National Cancer Institute (NCI) awarded a 5-year, $606,697 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Augusta University Research Institute, Inc. in Augusta, Georgia. The grant supports research aimed at suppressing the co-chaperone UNC45A to reprogram the immunosuppressive tumor microenvironment and enhance cancer treatment, particularly for triple-negative breast cancer. The specific objectives are to: 1) characterize the changes in the tumor microenvironment caused by loss of UNC45A, 2) define the molecular mechanisms by which UNC45A promotes an immunosuppressive environment, and 3) determine the therapeutic potential of UNC45A inhibition combined with radiation therapy. This research is expected to identify UNC45A as a novel immunotherapeutic target and develop innovative approaches to improve outcomes for patients with aggressive breast cancers.
Generated 1/28/25, 9:13 AM